MNMarvin D. Nelson

Marvin D. Nelson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marvin D. Nelson has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Patient and Family Perspectives on Point-of-Care Low-Field Brain Magnetic Resonance Imaging for Children in the Emergency Department, Intensive Care Unit, and Hospital Setting

    by Christina Lee, Jason Toliao, Kayla Guzman, Samantha Lozano, Payal Shah, Frank Gonzalez, Marvin Nelson, Jonathan Santoro, Ramón Durazo-Arvizu, Eamon Doyle, et al.


  • Open Access

    Supplementary Data 1 from Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial

    by Adam L. Green, Charles G. Minard, Xiaowei Liu, Stephanie L. Safgren, Kerice Pinkney, Lauren Harris, Gabrielle Link, John DeSisto, Stephan Voss, Marvin D. Nelson, et al.

    Supplemental Tables 1-10 and Supplemental Figure 1

  • Open Access

    Data from Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial

    by Adam L. Green, Charles G. Minard, Xiaowei Liu, Stephanie L. Safgren, Kerice Pinkney, Lauren Harris, Gabrielle Link, John DeSisto, Stephan Voss, Marvin D. Nelson, et al.

    Purpose:Selinexor is a first-in-class, central nervous system (CNS)–penetrant, oral inhibitor of exportin 1 (XPO1), the main nuclear exporter of many key tumor suppressors. We report a phase I trial of selinexor in children and adolescents with recurrent CNS and solid tumors (NCT02323880).Patients and Methods:A rolling six design was used to evaluate the maximum tolerated dose (MTD) and first dose pharmacokinetics of selinexor administered once (35–45 mg/m2) or twice (20–35 mg/m2) weekly during a 28-day cycle (part A). Ten additional patients with high-grade glioma (HGG) were treated at the MTD administered once weekly (part B).Results:In part A, 49 patients were enrolled. Continuous twice weekly dosing was limited by extended hematologic toxicity. The MTD on a twice weekly schedule for 3 weeks on/1 week off (twice weekly 3/1) was 20 mg/m2/dose. Dose-limiting toxicities (DLTs) on this schedule included fatigue, acute reversible neurologic changes, neutropenia, thrombocytopenia, and aspartate aminotransferase/alanine aminotransferase increase. On a continuous once weekly schedule, the MTD was 35 mg/m2/dose; DLTs included seizure and thrombocytopenia. In part B (HGG expansion), there were no additional DLTs observed. Non-DLTs included lymphopenia, leukopenia, neutropenia, thrombocytopenia, anorexia, fatigue, hypophosphatemia, nausea, and vomiting. There were no objective responses. The median number of cycles received was 1 (range, 1–9); eight of 59 patients (13.5%) received 5 to 9 cycles, five of whom had HGG.Conclusions:Selinexor-related toxicities were primarily hematologic and neurologic, requiring dose or dose-frequency reduction. The MTD and recommended initial phase II dose of selinexor in children and adolescents with recurrent solid and CNS tumors is 35 mg/m2/dose once weekly.

  • Metabolic and molecular correlates of medulloblastoma: Identification of molecular groups using in vivo 1H-MR spectroscopy

    by Benita Tamrazi, Alexander L Markowitz, Ashley S Margol, Marvin D Nelson, Mark D Krieger, Matija Snuderl, Jianling Ji, Steven Y Cen, Jennifer Cotter, Stefan Blüml

    Background: Accurate molecular classification of medulloblastoma is critical for prognosis and treatment planning, but current methods rely on surgical tissue sampling and molecular profiling. This study evaluated whether in vivo proton MR spectroscopy (¹H-MRS) can provide noninvasive metabolic markers to support presurgical molecular group stratification. Methods: In this single-center retrospective study, pretreatment ¹H-MRS data were analyzed from 95 pediatric patients with medulloblastoma (median age 7.4 years; 56 male). Single-voxel point-resolved spectroscopy (TE = 35 ms, TR = 1.5-2.0 s) were acquired during routine clinical MRI, adding approximately 5 minutes of scan time. Absolute metabolite concentrations and selected ratios were quantified using automated spectral fitting. Metabolic profiles were compared across molecular groups (group 3, n = 22; group 4, n = 35; sonic hedgehog [SHH], n = 26; wingless [WNT], n = 12) and assessed for qualitative concordance with prior ex vivo high-resolution HR-MAS NMR findings. Group differences were tested using Kruskal-Wallis with Dunn post hoc correction. Results: Significant metabolic differences were observed across molecular groups, with strong group effects for taurine, creatine, choline, glutamate, and γ-aminobutyric acid (GABA) (all P < .0015). Taurine was elevated in group 3 and group 4 relative to SHH (log₂FC = 1.77 and 1.40, adjusted P < 4 × 10⁻⁵). SHH tumors exhibited lower creatine compared with group 3, group 4, and WNT (adjusted P < .05). Glutamate was higher in SHH than in WNT, while WNT tumors showed increased choline and GABA relative to other groups (adjusted P < .05). In vivo patterns were qualitatively concordant with ex vivo NMR findings. Conclusions: In vivo ¹H-MRS is a widely available, clinically feasible imaging biomarker that complements existing diagnostics and supports presurgical stratification of medulloblastoma.

  • Open Access

    Supplementary Data 1 from Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial

    by Adam L. Green, Charles G. Minard, Xiaowei Liu, Stephanie L. Safgren, Kerice Pinkney, Lauren Harris, Gabrielle Link, John DeSisto, Stephan Voss, Marvin D. Nelson, et al.

    Supplemental Tables 1-10 and Supplemental Figure 1

  • Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial

    by Adam L. Green, Charles G. Minard, Xiaowei Liu, Stephanie L. Safgren, Kerice Pinkney, Lauren Harris, Gabrielle Link, John DeSisto, Stephan Voss, Marvin D. Nelson, et al.

    Purpose: Selinexor is a first-in-class, central nervous system (CNS)–penetrant, oral inhibitor of exportin 1 (XPO1), the main nuclear exporter of many key tumor suppressors. We report a phase I trial of selinexor in children and adolescents with recurrent CNS and solid tumors (NCT02323880). Patients and Methods: A rolling six design was used to evaluate the maximum tolerated dose (MTD) and first dose pharmacokinetics of selinexor administered once (35–45 mg/m2) or twice (20–35 mg/m2) weekly during a 28-day cycle (part A). Ten additional patients with high-grade glioma (HGG) were treated at the MTD administered once weekly (part B). Results: In part A, 49 patients were enrolled. Continuous twice weekly dosing was limited by extended hematologic toxicity. The MTD on a twice weekly schedule for 3 weeks on/1 week off (twice weekly 3/1) was 20 mg/m2/dose. Dose-limiting toxicities (DLTs) on this schedule included fatigue, acute reversible neurologic changes, neutropenia, thrombocytopenia, and aspartate aminotransferase/alanine aminotransferase increase. On a continuous once weekly schedule, the MTD was 35 mg/m2/dose; DLTs included seizure and thrombocytopenia. In part B (HGG expansion), there were no additional DLTs observed. Non-DLTs included lymphopenia, leukopenia, neutropenia, thrombocytopenia, anorexia, fatigue, hypophosphatemia, nausea, and vomiting. There were no objective responses. The median number of cycles received was 1 (range, 1–9); eight of 59 patients (13.5%) received 5 to 9 cycles, five of whom had HGG. Conclusions: Selinexor-related toxicities were primarily hematologic and neurologic, requiring dose or dose-frequency reduction. The MTD and recommended initial phase II dose of selinexor in children and adolescents with recurrent solid and CNS tumors is 35 mg/m2/dose once weekly.


  • Open Access

    Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children’s Oncology Group Study

    by Rishi R Lulla, Allen Buxton, Mark D Krailo, Margot A Lazow, Daniel R Boue, James L Leach, Tong Lin, James I Geller, Shiva Senthil Kumar, Marina N Nikiforova, et al.

    Outcomes for children with high-grade gliomas (HGG) remain poor. This multicenter phase II trial evaluated whether concurrent use of vorinostat or bevacizumab with focal radiotherapy (RT) improved 1-year event-free survival (EFS) compared to temozolomide in children with newly diagnosed HGG who received maintenance temozolomide and bevacizumab. Patients ≥ 3 and < 22 years with localized, non-brainstem HGG were randomized to receive RT (dose 54–59.4Gy) with vorinostat, temozolomide, or bevacizumab followed by 12 cycles of bevacizumab and temozolomide maintenance therapy. Among 90 patients randomized, the 1-year EFS for concurrent bevacizumab, vorinostat, or temozolomide with RT was 43.8% (±8.8%), 41.4% (±9.2%), and 59.3% (±9.5%), respectively, with no significant difference among treatment arms. Three- and five-year EFS for the entire cohort was 14.8% and 13.4%, respectively, with no significant EFS difference among the chemoradiotherapy arms. IDH mutations were associated with more favorable EFS (P = .03), whereas H3.3 K27M mutations (P = .0045) and alterations in PIK3CA or PTEN (P = .025) were associated with worse outcomes. Patients with telomerase- and alternative lengthening of telomeres (ALT)-negative tumors (n = 4) had an EFS of 100%, significantly greater than those with ALT or telomerase, or both (P = .002). While there was no difference in outcomes based on TERT expression, high TERC expression was associated with inferior survival independent of the telomere maintenance mechanism (P = .0012). Chemoradiotherapy with vorinostat or bevacizumab is not superior to temozolomide in children with newly diagnosed HGG. Patients with telomerase- and ALT-negative tumors had higher EFS suggesting that, if reproduced, mechanism of telomere maintenance should be considered in molecular-risk stratification in future studies.


  • Automated Segmentation of the Hippocampus in Pediatric Imaging

    by Rahimeh Rouhi, Jeffrey Tanedo, Iris Miao Wei, Malia Valder, Shreyash Zanjal, Niharika Gajawelli, Marvin Nelson, Sean Deoni, Yalin Wang, Marius George Linguraru, et al.

    The infant hippocampus plays a pivotal role in early brain development and is linked to cognitive and memory functions. Accurate delineation of the hippocampus is essential for studying normal brain development and detecting early abnormalities associated with various neurodevelopmental disorders. In this paper, different deep neural network models were trained for 3D-automatic segmentation of the hippocampus based on cross-validation on a cohort of T1-Weighted (T1W) images acquired from 100 subjects with ground truth. The models were tested on another image cohort of 86 subjects without ground truth. Ensembling the single-trained models during cross-validation resulted in the final segmentation. Among all the trained networks, nnUNet and SegResNet achieved the best average Dice Similarity Coefficient (DSC)=0.82±0.01 and 95th Hausdorff Distance (95HD)=2.45±1.10 mm, respectively, in 5-fold cross-validation. We presented a comprehensive comparison between different architectures in terms of their generalizability and effectiveness, suggesting the potential for developing on-the-fly automated segmentation of the hippocampus in pediatric MRI.

  • Neuroimaging of complications arising after CD19 chimeric antigen receptor T‐cell therapy: A review

    by Soniya N. Pinto, Chia‐Shang J. Liu, Marvin D. Nelson, Stefan Bluml, David Livingston, Benita Tamrazi

    Chimeric antigen receptor (CAR) T cells targeting the CD19 (cluster of differentiation 19) cell surface glycoprotein have emerged as a highly effective immunologic therapy in patients with relapsed or refractory B‐cell malignancies. The engagement of CAR T cells with CD19 on the surface of neoplastic B cells causes a systemic cytokine release, which can compromise the blood‐brain barrier and cause an immune effector cell‐associated neurotoxicity syndrome (ICANS). In a small proportion of ICANS patients who demonstrate neuroimaging abnormalities, certain distinct patterns have been recognized, including signal changes in the thalami, external capsule, and brainstem, the subcortical and/or periventricular white matter, the splenium of the corpus callosum, and the cerebellum. On careful review of the underlying pathophysiology of ICANS, we noticed that these changes closely mirror the underlying blood‐brain barrier disruption and neuroinflammatory and excitotoxic effects of the offending cytokines released during ICANS. Furthermore, other uncommon complications of CD19 CAR T‐cell therapy such as posterior reversible encephalopathy syndrome, ocular complications, and opportunistic fungal infections can be catastrophic if not diagnosed in a timely manner, with neuroimaging playing a significant role in management. In this narrative review, we will summarize the current literature on the spectrum of neuroimaging findings in ICANS, list appropriate differential diagnoses, and explore the imaging features of other uncommon central nervous system complications of CD19 CAR T‐cell therapy using illustrative cases from two tertiary care institutions.


  • Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo 1H-MR Spectroscopy

    by B. Tamrazi, S. Venneti, A. Margol, D. Hawes, S.Y. Cen, M. Nelson, A. Judkins, J. Biegel, S. Blüml

    BACKGROUND AND PURPOSE: Atypical teratoid/rhabdoid tumors are rare, aggressive central nervous system tumors that are predominantly encountered in very young children. Our aim was to determine whether in vivo metabolic profiles correlate with molecular features of central nervous system pediatric atypical teratoid/rhabdoid tumors. MATERIALS AND METHODS: Twenty confirmed patients with atypical teratoid/rhabdoid tumors who underwent MR spectroscopy were included in this study. In vivo metabolite levels of atypical teratoid/rhabdoid tumors were compared with molecular subtypes assessed by achaete-scute homolog 1 expression. Additionally, brain-specific creatine kinase levels were determined in tissue samples. RESULTS: In vivo creatine concentrations were higher in tumors that demonstrated achaete-scute homolog 1 expression compared with those without achaete-scute homolog 1 expression (3.42 ± 1.1 versus 1.8 ± 0.8 IU, P < .01). Additionally, levels of myo-inositol (mI) (9.0 ± 1.5 versus 4.7 ± 3.6 IU, P < .05) were significantly different, whereas lipids approached significance (44 ± 20 versus 80 ± 30 IU, P = .07) in these 2 cohorts. Higher brain-specific creatine kinase levels were observed in the cohort with achaete-scute homolog 1 expression (P < .05). Pearson correlation analysis showed a significant positive correlation of brain-specific creatine kinase with absolute creatine (P < .05) and myo-inositol (P < .05) concentrations. CONCLUSIONS: In vivo MR spectroscopy may predict key molecular features of atypical teratoid/rhabdoid tumors at initial diagnosis, leading to timely patient risk stratification and accelerating the development of targeted therapies.